753387-55-2

Downstream Products

• 1041402-59-8 2-amino-4-[2-{5-(N,N'-bis((S)-1-ethoxycarbonyl)cyclohexanylmethyl)phosphonamido}furanyl]-5-propylsulfanylthiazole 
• 906375-45-9 (2S,4R)-1-{(S)-2-[3-(3-Benzyloxy-phenyl)-3-methyl-ureido]-2-cyclohexyl-acetyl}-4-(3-benzyloxy-propoxy)-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 906375-48-2 (5S,8S,10R)-5-Cyclohexyl-2-methyl-3,6-dioxo-11,15-dioxa-2,4,7-triaza-tricyclo[14.3.1.1^7,10]henicosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-8-carboxylic acid tert-butyl ester 
• 906375-51-7 (5S,8S,10R)-5-Cyclohexyl-2-methyl-3,6-dioxo-11,15-dioxa-2,4,7-triaza-tricyclo[14.3.1.1^7,10]henicosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-8-carboxylic acid 
• 367260-22-8 (S)-[3-(3-Benzyloxy-phenyl)-3-methyl-ureido]-cyclohexyl-acetic acid ethyl ester 
• 367261-52-7 (S)-Cyclohexyl-(4-nitro-phenoxycarbonylamino)-acetic acid ethyl ester 

Relevant academic research and scientific papers

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.